{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:19:52Z","timestamp":1776842392297,"version":"3.51.2"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health (NIH)","award":["R01AI154542"],"award-info":[{"award-number":["R01AI154542"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Lyme disease (LD) is the most common tick-borne illness in the United States (U.S.), Europe, and Asia. Borrelia burgdorferi, a spirochete bacterium transmitted by the tick vector Ixodes scapularis, causes LD in the U.S. If untreated, Lyme arthritis, heart block, and meningitis can occur. Given the absence of a human Lyme disease vaccine, we developed a vaccine using the rabies virus (RABV) vaccine vector BNSP333 and an outer surface borrelial protein, BBI39. BBI39 was previously utilized as a recombinant protein vaccine and was protective in challenge experiments; therefore, we decided to utilize this protective antigen in a rabies virus-vectored vaccine against Borrelia burgdorferi. To incorporate BBI39 into the RABV virion, we generated a chimeric BBI39 antigen, BBI39RVG, by fusing BBI39 with the final amino acids of the RABV glycoprotein by molecular cloning and viral recovery with reverse transcription genetics. Here, we have demonstrated that the BBI39RVG antigen was incorporated into the RABV virion via immunofluorescence and Western blot analysis. Mice vaccinated with our BPL inactivated RABV-BBI39RVG (BNSP333-BBI39RVG) vaccine induced high amounts of BBI39-specific antibodies, which were maintained long-term, up to eight months post-vaccination. The BBI39 antibodies neutralized Borrelia in vaccinated mice when challenged with Borrelia burgdorferi by either syringe injection or infected ticks and they reduced the Lyme disease pathology of arthritis in infected mouse joints. Overall, the RABV-based LD vaccine induced more and longer-term antibodies compared to the recombinant protein vaccine. This resulted in lower borrelial RNA in RABV-based vaccinated mice compared to recombinant protein vaccinated mice. The results of this study indicate the successful use of BBI39 as a vaccine antigen and RABV as a vaccine vector for LD.<\/jats:p>","DOI":"10.3390\/vaccines12010078","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T07:47:16Z","timestamp":1705045636000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Development of a Rabies Virus-Vectored Vaccine against Borrelia burgdorferi, Targeting BBI39"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4809-0567","authenticated-orcid":false,"given":"Shantel","family":"Rios","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Jefferson Vaccine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibek","family":"Bhattachan","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Maryland, College Park, MD 20740, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kruthi","family":"Vavilikolanu","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Maryland, College Park, MD 20740, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysoula","family":"Kitsou","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Maryland, College Park, MD 20740, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utpal","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Maryland, College Park, MD 20740, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Jefferson Vaccine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3201\/eid2702.202731","article-title":"Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010\u20132018","volume":"27","author":"Kugeler","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","first-page":"e30673","article-title":"The Spectrum of Erythema Migrans in Early Lyme Disease: Can We Improve Its Recognition?","volume":"14","author":"Schotthoefer","year":"2022","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Adrion, E.R., Aucott, J., Lemke, K.W., and Weiner, J.P. (2015). Health care costs, utilization and patterns of care following Lyme disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116767"},{"key":"ref_4","unstructured":"Centers for Disease Control and Prevention (2021, May 06). Signs and Symptoms of Untreated Lyme Disease, Available online: https:\/\/www.cdc.gov\/lyme\/signs_symptoms\/index.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI21681","article-title":"The emergence of Lyme disease","volume":"113","author":"Steere","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_6","unstructured":"Centers for Disease Control and Prevention (2021, May 06). Post-Treatment Lyme Disease Syndrome, Available online: https:\/\/www.cdc.gov\/lyme\/postlds\/index.html."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Comstedt, P., Schuler, W., Meinke, A., and Lundberg, U. (2017). The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184357"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41541-020-0183-8","article-title":"Design of a broadly reactive Lyme disease vaccine","volume":"5","author":"Kamp","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_9","first-page":"191","article-title":"Human and Veterinary Vaccines for Lyme Disease","volume":"42","author":"Hatke","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199807233390401","article-title":"Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group","volume":"339","author":"Steere","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41541-022-00429-5","article-title":"The year that shaped the outcome of the OspA vaccine for human Lyme disease","volume":"7","author":"Dattwyler","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100079","DOI":"10.1016\/j.jvacx.2020.100079","article-title":"VANGUARD(R)crLyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs","volume":"6","author":"Marconi","year":"2020","journal-title":"Vaccine X"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jix036","article-title":"Borrelia burgdorferi BBI39 Paralogs, Targets of Protective Immunity, Reduce Pathogen Persistence Either in Hosts or in the Vector","volume":"215","author":"Singh","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI9427","article-title":"Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A","volume":"106","author":"Pal","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/cid\/ciz872","article-title":"Protective Immunity and New Vaccines for Lyme Disease","volume":"70","author":"Arnaboldi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2006.05.010","article-title":"Rabies virus glycoprotein as a carrier for anthrax protective antigen","volume":"353","author":"Smith","year":"2006","journal-title":"Virology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.vaccine.2011.04.045","article-title":"Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge","volume":"29","author":"Mustafa","year":"2011","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-020-00248-6","article-title":"Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2","volume":"5","author":"Kurup","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0950268899002666","article-title":"An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species","volume":"123","author":"Vos","year":"1999","journal-title":"Epidemiol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1128\/JVI.75.23.11496-11502.2001","article-title":"Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein","volume":"75","author":"Mebatsion","year":"2001","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.virol.2012.07.020","article-title":"A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence","volume":"434","author":"Papaneri","year":"2012","journal-title":"Virology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-387040-7.00009-3","article-title":"Rabies virus as a research tool and viral vaccine vector","volume":"79","author":"Gomme","year":"2011","journal-title":"Adv. Virus Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41541-023-00615-z","article-title":"Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge","volume":"8","author":"Yankowski","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41541-022-00532-7","article-title":"Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity","volume":"7","author":"Yankowski","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Hagen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/infdis\/jiv251","article-title":"Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses","volume":"212","author":"Willet","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-023-00663-5","article-title":"GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus","volume":"8","author":"Scher","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","article-title":"An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models","volume":"214","author":"Johnson","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","article-title":"Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic","volume":"77","author":"McGettigan","year":"2003","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/infdis\/jis930","article-title":"Novel microbial virulence factor triggers murine lyme arthritis","volume":"207","author":"Yang","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1073\/pnas.93.21.11359","article-title":"Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles","volume":"93","author":"Schnell","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1073\/pnas.93.14.7310","article-title":"Highly stable expression of a foreign gene from rabies virus vectors","volume":"93","author":"Mebatsion","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.vaccine.2019.10.073","article-title":"Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes","volume":"38","author":"Federizon","year":"2020","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/167.1.158","article-title":"Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: A serodiagnostic test","volume":"167","author":"Callister","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3389\/fimmu.2018.00959","article-title":"The Classical Complement Pathway Is Required to Control Borrelia burgdorferi Levels During Experimental Infection","volume":"9","author":"Zhi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2595","DOI":"10.1002\/jmr.2595","article-title":"Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions","volume":"30","author":"Shandilya","year":"2017","journal-title":"J. Mol. Recognit."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.ymthe.2023.07.022","article-title":"Development of an mRNA-lipid nanoparticle vaccine against Lyme disease","volume":"31","author":"Pine","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJM199807233390402","article-title":"A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium","volume":"339","author":"Sigal","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1126\/science.281.5377.703","article-title":"Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis","volume":"281","author":"Gross","year":"1998","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wormser, G.P. (2022). A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease. Diagn. Microbiol. Infect. Dis., 102.","DOI":"10.1016\/j.diagmicrobio.2021.115572"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1016\/j.vaccine.2011.05.010","article-title":"A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen","volume":"29","author":"Xiao","year":"2011","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1020134","DOI":"10.3389\/fimmu.2023.1020134","article-title":"DNA lipid nanoparticle vaccine targeting outer surface protein C affords protection against homologous Borrelia burgdorferi needle challenge in mice","volume":"14","author":"Pfeifle","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eabj9827","DOI":"10.1126\/scitranslmed.abj9827","article-title":"mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent","volume":"13","author":"Sajid","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, L., Chen, J., Shen, C., Wang, G., Lu, Z., Zeng, D., Gao, Y., Chen, H., Xia, N., and Chen, Y. (2022). Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets. Vaccines, 10.","DOI":"10.3390\/vaccines10081304"},{"key":"ref_47","first-page":"100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health\u2013Eur."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1016\/j.vaccine.2021.11.003","article-title":"Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies","volume":"39","author":"Matias","year":"2021","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1128\/IAI.68.9.5190-5197.2000","article-title":"T-cell-independent responses to Borrelia burgdorferi are critical for protective immunity and resolution of lyme disease","volume":"68","author":"McKisic","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12533","DOI":"10.1073\/pnas.94.23.12533","article-title":"Therapeutic passive vaccination against chronic Lyme disease in mice","volume":"94","author":"Zhong","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1128\/IAI.68.10.5496-5501.2000","article-title":"Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4","volume":"68","author":"Munson","year":"2000","journal-title":"Infect. Immun."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/1\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:45:27Z","timestamp":1760103927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/1\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["vaccines12010078"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12010078","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]}}}